{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T22:10:08Z","timestamp":1736460608748,"version":"3.32.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pancreatology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.pan.2024.03.015","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T16:09:38Z","timestamp":1712246978000},"page":"616-623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment outcomes of gemcitabine plus nab-paclitaxel in pancreatic cancer patients with malignant ascites"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4570-6383","authenticated-orcid":false,"given":"Kanae","family":"Inoue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1945-0795","authenticated-orcid":false,"given":"Koh","family":"Fukushi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8771-824X","authenticated-orcid":false,"given":"Tomonao","family":"Taira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Shibuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Satake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhito","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Imaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9496-3278","authenticated-orcid":false,"given":"Shuichi","family":"Mitsunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4050-2086","authenticated-orcid":false,"given":"Masafumi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pan.2024.03.015_bib1","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","article-title":"Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes","volume":"24","author":"McGuigan","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.pan.2024.03.015_bib2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/MPA.0b013e3182021376","article-title":"Construction and validation of a prognostic index for patients with metastatic pancreatic adenocarcinoma","volume":"40","author":"Morizane","year":"2011","journal-title":"Pancreas"},{"key":"10.1016\/j.pan.2024.03.015_bib3","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/MPA.0b013e318205e332","article-title":"Pancreatic carcinomas in a 60-year, institute-based autopsy material with special emphasis of metastatic pattern","volume":"40","author":"Blastik","year":"2011","journal-title":"Pancreas"},{"key":"10.1016\/j.pan.2024.03.015_bib4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/MPA.0b013e31825abf8c","article-title":"Incidence, prognosis, and possible treatment strategies of peritoneal carcinomatosis of pancreatic origin: a population-based study","volume":"42","author":"Thomassen","year":"2013","journal-title":"Pancreas"},{"key":"10.1016\/j.pan.2024.03.015_bib5","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.clcc.2016.04.014","article-title":"Pancreas adenocarcinoma: ascites, clinical manifestations, and management implications","volume":"15","author":"Hicks","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.pan.2024.03.015_bib6","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/MPA.0000000000000290","article-title":"Pancreatic cancer with malignant ascites: clinical features and outcomes","volume":"44","author":"Takahara","year":"2015","journal-title":"Pancreas"},{"key":"10.1016\/j.pan.2024.03.015_bib7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1477-7819-4-16","article-title":"Prognostic significance of new onset ascites in patients with pancreatic cancer","volume":"4","author":"Zervos","year":"2006","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.pan.2024.03.015_bib8","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.gie.2009.08.025","article-title":"Survival in patients with pancreatic cancer after the diagnosis of malignant ascites or liver metastases by eus-fna","volume":"71","author":"DeWitt","year":"2010","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.pan.2024.03.015_bib9","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pan.2024.03.015_bib10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00280-016-2972-3","article-title":"Phase i\/ii study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer","volume":"77","author":"Ueno","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.pan.2024.03.015_bib11","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.pan.2021.03.006","article-title":"Improved prognosis of pancreatic cancer patients with peritoneal metastasis","volume":"21","author":"Takeda","year":"2021","journal-title":"Pancreatology"},{"key":"10.1016\/j.pan.2024.03.015_bib12","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s10637-016-0369-0","article-title":"Intravenous and intraperitoneal paclitaxel with s-1 for treatment of refractory pancreatic cancer with malignant ascites","volume":"34","author":"Takahara","year":"2016","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.pan.2024.03.015_bib13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/jhbp.447","article-title":"Survival benefit of intravenous and intraperitoneal paclitaxel with s-1 in pancreatic ductal adenocarcinoma patients with peritoneal metastasis: a retrospective study in a single institution","volume":"24","author":"Satoi","year":"2017","journal-title":"J\u00a0Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.pan.2024.03.015_bib14","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3748\/wjg.v12.i9.1412","article-title":"Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients","volume":"12","author":"Kobayashi","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.pan.2024.03.015_bib15","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12885-018-4057-7","article-title":"A\u00a0retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites","volume":"18","author":"Matsumoto","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pan.2024.03.015_bib16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10120-011-0016-6","article-title":"Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase ii trial of paclitaxel for malignant ascites secondary to advanced\/recurrent gastric cancer","volume":"14","author":"Imamoto","year":"2011","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.pan.2024.03.015_bib17","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10120-020-01043-x","article-title":"Randomized phase ii\/iii study of 5-fluorouracil\/l-leucovorin versus 5-fluorouracil\/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (jcog1108\/wjog7312g)","volume":"23","author":"Nakajima","year":"2020","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.pan.2024.03.015_bib18","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/jjco\/hyq117","article-title":"Weekly paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study","volume":"40","author":"Shukuya","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.pan.2024.03.015_bib19","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/bjs.11792","article-title":"Phase i\/ii study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis","volume":"107","author":"Yamada","year":"2020","journal-title":"Br J Surg"},{"key":"10.1016\/j.pan.2024.03.015_bib20","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S2468-1253(16)30219-9","article-title":"Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (absolute): an open-label, randomised, non-inferiority, phase 3 trial","volume":"2","author":"Shitara","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.pan.2024.03.015_bib21","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1186\/s12885-020-07047-1","volume":"20","author":"Hirata","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pan.2024.03.015_bib22","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ejca.2005.11.018","article-title":"Malignant ascites: systematic review and guideline for treatment","volume":"42","author":"Becker","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pan.2024.03.015_bib23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4240\/wjgs.v4.i4.87","article-title":"Malignant ascites: a review of prognostic factors, pathophysiology and therapeutic measures","volume":"4","author":"Sangisetty","year":"2012","journal-title":"World J Gastrointest Surg"},{"key":"10.1016\/j.pan.2024.03.015_bib24","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/ags3.12386","article-title":"An ascites grading system for predicting the prognosis of gastric cancer with peritoneum dissemination","volume":"4","author":"Honda","year":"2020","journal-title":"Ann Gastroenterol Surg"},{"key":"10.1016\/j.pan.2024.03.015_bib25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10147-017-1198-7","article-title":"First-line bolus 5-fluorouracil plus leucovorin for peritoneally disseminated gastric cancer with massive ascites or inadequate oral intake","volume":"23","author":"Hara","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.pan.2024.03.015_bib26","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/jjco\/hyi109","article-title":"A\u00a0new, accurate and conventional five-point method for quantitative evaluation of ascites using plain computed tomography in cancer patients","volume":"35","author":"Oriuchi","year":"2005","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.pan.2024.03.015_bib27","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised recist guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pan.2024.03.015_bib28","first-page":"1744","article-title":"Predictive factors for tumor response to chemotherapy in patients with pancreatic cancer","volume":"47","author":"Fujishiro","year":"2000","journal-title":"Hepato-Gastroenterology"},{"key":"10.1016\/j.pan.2024.03.015_bib29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10637-020-00982-7","article-title":"A\u00a0phase i study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis","volume":"39","author":"Takahara","year":"2021","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.pan.2024.03.015_bib30","first-page":"271","article-title":"Improvement of treatment outcomes for metastatic pancreatic cancer: a real-world data analysis","volume":"33","author":"Sasaki","year":"2019","journal-title":"In\u00a0Vivo"}],"container-title":["Pancreatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390324000772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390324000772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T21:35:48Z","timestamp":1736458548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1424390324000772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1424390324000772"],"URL":"https:\/\/doi.org\/10.1016\/j.pan.2024.03.015","relation":{},"ISSN":["1424-3903"],"issn-type":[{"type":"print","value":"1424-3903"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment outcomes of gemcitabine plus nab-paclitaxel in pancreatic cancer patients with malignant ascites","name":"articletitle","label":"Article Title"},{"value":"Pancreatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pan.2024.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 IAP and EPC. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}